300942 易瑞生物
按盤價 
10.550 +1.760 (+20.023%)
10.550 +1.760 (+20.023%) | 2024/09 - 九個月 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 0.458 | -20.388 | 8.689 | 31.665 | 12.150 |
| 總資產報酬率 ROA (%) | 0.285 | -14.015 | 6.814 | 26.200 | 10.286 |
| 投入資產回報率 ROIC (%) | 0.309 | -15.477 | 7.659 | 29.590 | 11.415 | 邊際利潤分析 |
| 銷售毛利率 (%) | 66.093 | 49.929 | 56.506 | 71.632 | 75.366 |
| 營業利潤率 (%) | 3.206 | -68.987 | 14.283 | 44.897 | 29.059 |
| 息稅前利潤/營業總收入 (%) | 6.967 | -71.069 | 12.577 | 45.693 | 32.821 |
| 淨利潤/營業總收入 (%) | 1.890 | -72.798 | 12.034 | 39.574 | 25.323 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | -17.381 | 44.059 | 138.511 | 92.300 | 95.754 |
| 價值變動淨收益/利潤總額(%) | -80.753 | 30.419 | 2.820 | 3.606 | 11.924 |
| 營業外收支淨額/利潤總額(%) | -7.381 | 1.404 | -3.395 | -0.089 | -1.571 | 償債能力分析 |
| 流動比率 (X) | 5.175 | 5.387 | 3.376 | 5.731 | 6.735 |
| 速動比率 (X) | 4.902 | 5.158 | 2.872 | 5.132 | 5.947 |
| 資產負債率 (%) | 38.081 | 37.425 | 24.777 | 17.869 | 15.914 |
| 帶息債務/全部投入資本 (%) | 32.626 | 29.327 | 10.962 | 1.914 | -- |
| 股東權益/帶息債務 (%) | 203.781 | 234.117 | 763.464 | 4,870.858 | 5,359.819 |
| 股東權益/負債合計 (%) | 162.443 | 167.253 | 303.659 | 458.756 | 528.428 |
| 利息保障倍數 (X) | 1.750 | 64.635 | -10.167 | 54.695 | 7.794 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 135.979 | 113.357 | 47.412 | 48.002 | 0.000 |
| 存貨周轉天數 (天) | 176.801 | 186.842 | 117.164 | 165.069 | 0.000 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 26/11/2024 15:35 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
